LI
CNCE

Leap Investments’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Leap Investments’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-15,344
Closed -$184K – 529
2019
Q2 		$184K Buy
+15,344
New +$165K 0.25% 165

Other funds holding CNCE

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

Leap Investments's CNCE Position: Q3 2019 in Review

Leap Investments sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q3 2019, closing a stake of 15,344 shares — an estimated $184K sold.

Leap Investments first reported a position in CNCE in Q2 2019 and held it in 1 quarter. The position peaked at $184K in Q2 2019. 80 funds tracked by Wall St. Rank hold CNCE as of Q3 2019.

  • Leap Investments reported no remaining Concert Pharmaceuticals, Inc. position as of Q3 2019 after selling out during the quarter.
  • Leap Investments sold 15,344 Concert Pharmaceuticals, Inc. shares in Q3 2019, an estimated $184K.
  • Leap Investments first reported a position in Concert Pharmaceuticals, Inc. in Q2 2019 and held it in 1 quarter.
  • Leap Investments's Concert Pharmaceuticals, Inc. position peaked at $184K in Q2 2019.
  • 80 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q3 2019.

Based on Leap Investments's 13F filing for Q3 2019, filed 13 Nov 2019.